On Tuesday, Shares of Boston Scientific Corporation (NYSE:BSX), dropped -1.28% to $17.75.
Boston Scientific Corporation, generated sales of $1.768 billion during the first quarter ended March 31, 2015, contrast to the company’s guidance range for the quarter of $1.740 to $1.800 billion. This represents 6 percent operational revenue growth (constant currency basis, not taking into account divested businesses) and flat revenue on a stated basis, all contrast to the preceding year period. The company achieved adjusted earnings per share of $0.21 for the period, contrast to $0.20 a year ago, which represents 6 percent growth, and stated a GAAP loss of $1 million, or $(0.00) per share, contrast to earnings per share of $0.10 a year ago.
First quarter financial results and recent developments:
- Achieved first quarter sales of $1.768 billion, representing 6 percent operational revenue growth and flat revenue on a stated basis, all contrast to the preceding year period.
- Delivered first quarter adjusted earnings per share of $0.21, which represents 6 percent growth contrast to the preceding year period, contrast to the company’s guidance range of $0.19 to $0.21 per share. Stated first quarter GAAP loss of $1 million, or $(0.00) per share, contrast to the company’s guidance range of $0.07 to $0.11 per share, primarily due to litigation-related charges.
- Delivered first quarter revenue growth of 10 percent in Cardiovascular, 4 percent in Rhythm Administration, and 4 percent in MedSurg, all on a constant currency basis over the preceding year period.
- Achieved first quarter International constant currency revenue growth of 7 percent over the preceding year period, primarily driven by 6 percent growth in Europe and 7 percent growth in the Asia, Middle East and Africa (AMEA) region.
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in three segments: Cardiovascular, Rhythm Administration, and MedSurg.
Shares of Keysight Technologies, Inc. (NYSE:KEYS), declined -1.16% to $33.94, during its last trading session.
Keysight Technologies, unveiled WaferPro Express 2015, a measurement software platform for the automated characterization of wafer-level devices and circuit components. By efficiently controlling all components in a wafer-level measurement system (instruments and wafer probers alike), WaferPro Express reduces measurement setup complexity and provides a unified platform for efficient automated measurement and data administration.
High-volume wafer-level measurements are no longer exclusive to the semiconductor foundry production floor. Recently, many R&D teams measure high-volume data for applications such as device modeling, process monitoring, reliability and component characterization; often at different temperatures. As a result, automated probers are becoming standard in R&D device characterization labs.
A key breakthrough in WaferPro Express 2015 is its exclusive integration with Cascade Microtech’s Velox 2.0 probe station control software. WaferPro Express and Velox 2.0 are integrated through Cascade Microtech’s WaferSync, a jointly developed two-way communication link. The link allows for complete wafer map synchronization, which enables easy and error-free information exchange between the software, counting wafer alignment, sites and die information.
The new WaferPro Express link to Velox 2.0, coupled with major usability improvements, allows test engineers to quickly setup measurement systems. To further maximize efficiency during RF measurement, WaferPro Express periodically monitors the stability of the RF calibration. Doing so minimizes the time spent collecting inaccurate data.
Keysight Technologies, Inc. provides electronic measurement solutions to the communications and electronics industries in the United States and internationally. It operates through two segments: Measurement Solutions, and Customer Support and Services.
At the end of Tuesday’s trade, Shares of AstraZeneca PLC (NYSE:AZN), dwindled -1.14% to $69.95.
Bina Technologies, Inc., a member of the Roche Group and AstraZeneca, declared that they have reached a contract for AstraZeneca to become the first member to join the Bina Alliance Program and to further develop the Bina Genomic Administration Solution (GMS). AstraZeneca will utilize the Bina GMS as an enterprise platform to support its development work across three main therapeutic areas: oncology, cardiovascular and metabolic disease, and respiratory, inflammation and autoimmunity.
Bina’s proprietary technology enables translational and academic researchers to perform fast and scalable analyses to maximize the value of genomic data. Under the terms of the agreement, AstraZeneca will adopt Bina GMS globally to support enterprise genomic data analysis and administration. Bina in turn will provide AstraZeneca with direct access to its scientific and engineering teams to further develop the Bina GMS for pharmaceutical applications.
AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection, and neuroscience diseases worldwide.
Finally, XL Group plc (NYSE:XL), ended its last trade with -1.06% loss, and closed at $37.41.
XL GROUP, declared that it has published its Global Loss Triangles for the year ending December 31, 2014. These documents are accessible in the Investor Relations section of XL’s website located at www.xlgroup.com.
XL GROUP Public Limited Company, an insurance and reinsurance company, provides property, casualty, and specialty products to industrial, commercial, and professional firms; and insurance companies and other enterprises worldwide.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
